GNRH1 and prostate carcinoma: Currently, the open-label randomized REPLACE-RV study aims to prospectively evaluate the risk for major adverse cardiovascular events in patients with prostate cancer treated with the GnRH antagonist relugolix compared to the GnRH agonist leuprolide acetate.